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Abstract
Background: Bacterial vaginosis (BV) is common in women who have sex with women. While cross-sectional data support a
role for sexual transmission, risks for incident BV have not been prospectively studied in this group.
Methodology/Principal Findings: We studied risks for BV acquisition in a prospective cohort study of women (age 16–35
years) who reported sex with other women ($1 partner, prior year). Women were followed for one year with examinations
at quarterly visits and for genital symptoms at any time. Species-specific 16S rRNA gene PCRs for BV-associated bacteria
(BVAB) were applied to vaginal fluid obtained at enrollment. Sexual behaviors were ascertained by computer-assisted
interview. Of 335 participants, 239 had no BV at baseline; 199 were seen in follow-up (median follow-up 355 days, 4.0 visits/
subject). Forty women experienced $1 BV episode. Risks for incident BV were presentation #14 days since onset of menses
(hazard ratio (HR) 2.3 (95% CI, 1.2–4.7), report of new sex partner with BV history (HR 3.63 (1.1–11.9)), change in vaginal
discharge (HR 2.6 (1.3–5.2)) and detection of any of several BVAB in vaginal fluid at enrollment, including BVAB1 (HR 6.3
(1.4–28.1)), BVAB2 (HR 18.2 (6.4–51.8)), BVAB3 (HR 12.6 (2.7–58.4)), G. vaginalis (HR 3.9 (1.5–10.4)), Atopobium vaginae (HR 4.2
(1.9–9.3)), Leptotrichia spp (9.3 (3.0–24.4)), and Megasphaera-1 (HR 11.5 (5.0–26.6)). Detection of Lactobacillus crispatus at
enrollment conferred reduced risk for subsequent BV (HR 0.18 (0.08–0.4)). Detailed analysis of behavioral data suggested a
direct dose-response relationship with increasing number of episodes of receptive oral-vulvovaginal sex (HR 1.02 (95% CI,
1.00–1.04).
Conclusions/Significance: Vaginal detection of several BVAB in BV-negative women predicted subsequent BV, suggesting
that changes in vaginal microbiota precede BV by weeks or months. BV acquisition was associated with report of new
partner with BV; associations with sexual practices – specifically, receptive oral sex – require further investigation.
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Introduction
Bacterial vaginosis (BV) is the most prevalent vaginal infection
in reproductive age women, and has been consistently associated
with adverse outcomes related to the upper genital tract, and with
increased risk of HIV acquisition.[1,2,3] Of 3,739 women enrolled
during 2001–2004 in a nationally representative sample of the
U.S. civilian non-institutionalized population, almost one in three
(29.2%; 95% C.I. 27.2–31.3) had BV by Gram stain of vaginal
fluid.[4,5]
Microbiologically, BV is characterized by depletion of hydrogen
peroxide-producing lactobacilli that characterize normal vaginal
microbiota, with profound overgrowth of anaerobic bacteria.[6]
However, the etiology of BV remains elusive. Several cross-
sectional studies have reported a wide variety of risks for this
common condition, including Black race, douching, smoking,
menses, chronic stress, and sexual behaviors (including higher
numbers of male sex partners, unprotected vaginal intercourse,
anal intercourse, and sex with other women).[7,8,9,10,11,12,13]
Fewer studies have followed women prospectively for incident BV.
These studies have reported that Black race, report of regular male
sex partner or of a female partner during follow-up, vaginal
hygiene behaviors, and higher Nugent score at initial evaluation
were risks.[14,15,16] One study with 619 woman-years of follow-
up found that BV acquisition was independently associated with
black race, cigarette smoking, vaginal intercourse, receptive anal
sex before vaginal intercourse, sex with an uncircumcised male
partner, lack of precedent hydrogen peroxide-producing vaginal
lactobacilli, and detection of HSV-2 serum antibodies at the visit
prior to BV diagnosis.[17]
Women who havesex with women have had a high prevalence of
BV (25%–52%) in several cross-sectional studies,[4,10,18,19,20,21]
We have previously reported risks for prevalent BV in a group of
women who reported sex with women in the previous year; these
included higher lifetime number of female sex partners, shared use
of a vaginally inserted sex toy, and oral-anal sex with a female
partner.[10] However, rate of and risks for BV acquisition have not
been reported for this group of women. Thus, we assessed risks for
BV acquisition in lesbian and bisexual women followed for one year
in a prospective study of vaginal microbiota. In addition to
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BV, we incorporated two novel elements. First, we used
comprehensive computer-assisted self-interview (CASI) to assess
behavioral risks. CASI has been shown to yield significantly higher
rates of disclosure for same-sex behavior and undesirable social
behaviors when compared directly with self-administered question-
naires.[22,23,24,25] CASI also provides other benefits, including
standardized delivery of survey content, eliminating variation in
interviewer or day, and computer-controlled branching, automated
consistency and range checking. Second, we applied species-specific
qualitative 16S rRNA gene polymerase chain reaction (PCR) assays
for various BV-associated bacteria (BVAB)[26] to vaginal fluid
obtained at participants’ enrollment visit, and considered this as a
baseline characteristic in analysis of risks for subsequent acquisition
of BV.
Methods
Objectives
We aimed to define risks for acquisition of BV among women
who were sexually active with other women, with attention to
detailed assessment of baseline vaginal microbiota and prospective
assessment of behavioral risks, including sexual practices.
Participants
The study population was composed of women aged 16 to 35
years who reported sex with at least one other woman in the
previous year who responded to recruitment through advertise-
ments, media, and community referral between October 2003 and
December 2006.
Investigations Undertaken
At enrollment, subjects completed an extensive computer-
assisted self-interview (CASI) on demographics and medical,
reproductive and sexual history. The CASI is self-administered
with a computer providing text and directly recording respon-
dents’ answers without an interviewer’s participation. The CASI
included detailed information on number and gender of recent
and lifetime sex partners, douching practices (history of douching,
frequency, indication, solution), frequency of specific sexual
practices, menstrual history, hormonal contraception, and antibi-
otic use. Participants underwent standardized examination
including collection of vaginal fluid for Gram stain, saline
microscopy, pH measurement, potassium hydroxide evaluation,
and culture of Lactobacillus species and Trichomonas vaginalis.
Cultures for Lactobacillus, and determination of hydrogen peroxide
production, were performed as previously described.[27] To
obtain specimens for bacterium-specific PCR assays, a polyure-
thane foam swab (Catch-All, Epicentre Biotechnologies, Madison,
WI) was brushed against the lateral vaginal wall and re-sheathed
and frozen immediately in a 280u freezer until DNA extraction.
Bacterial vaginosis was diagnosed if three of four clinical (Amsel)
criteria (vaginal pH.4.5, clue cells on saline microscopy .20% of
epithelial cells, amine odor on addition of potassium hydroxide,
and homogeneous vaginal discharge) were present[28] and Gram
stain of vaginal fluid confirmed abnormal microbiota (Nugent
score .3).[5] Vulvovaginal candidiasis was diagnosed if partici-
pants reported a recent change in vaginal discharge or vulvar
itching, and if 10% KOH preparation of vaginal fluid demon-
strated yeast forms. All participants were asked to return for three
subsequent quarterly visits (total duration of follow-up, one year)
or for evaluation at any time if genitourinary symptoms occurred.
Women with BV at any time during the study were treated with
vaginal metronidazole gel (37.5 mg nightly for 5 days) or, if
metronidazole was not tolerated, vaginal clindamycin cream (2%
(5 g) nightly for 7 days).
Microbiology. For DNA extraction, vaginal swabs for
bacterial PCR were placed in 15 mL conical vials with 2 mL of
saline and vortex mixed for 1 minute to dislodge cells. The solution
was centrifuged at 14,000 rpm for 10 minutes, and the pellet
resuspended in 100 ml supernatant. DNA was extracted from the
pellet using the Ultra Clean Soil DNA Kit (MoBio, Carlsbad, CA)
according to manufacturer’s instructions. DNA was eluted from
silica columns in a volume of 150 uL buffer. Sham digests using a
swab without human contact were performed with each round of
DNA extraction (every 10–25 samples) to control for
contamination that may arise from kit reagents or collection
swabs.
Bacterium specific PCR assays were developed based on
detection of species-specific regions of the 16S rRNA gene. rDNA
sequences from vaginal bacteria detected by broad range rDNA
PCR were aligned.[29] Primers were designed to target highly
variable regions of the bacterial 16S rRNA gene that appear
unique for each species. PCR assays were developed for 17
bacterial species that were commonly detected in vaginal
samples.[26] Each 50 ml PCR reaction contained 1X PCR Buffer
II, 2 mM magnesium chloride, 0.8 mM deoxyribonucleotide
triphosphate mix, 1 unit AmpliTaq Gold DNA polymerase (all
from Applied Biosystems, Foster City, CA), 0.2 uM each of
forward and reverse primer, and 1 uL of template DNA. PCR
conditions included a pre-melt at 95uC for 10 minutes; then 40–45
cycles of 95uC for 30 seconds (melt), 53–62uC for 30 seconds
(annealing), and 72uC for 30 seconds (extension); followed by a
final extension at 72uC for 7 minutes. PCR products were
visualized after electrophoresis in 2% agarose gels and staining
with ethidium bromide. Bacterial PCR assays were optimized so
that each assay was capable of detecting #100 molecules of cloned
16S rDNA per reaction, though most assays could detect 1–10
molecules. Every PCR with a visible band of the expected size on
gel electrophoresis was sequenced (BigDye version 3, Applied
Biosystems) to confirm that the PCR product had at least 99%
similarity with the expected bacterial target, thereby assuring
bacterial specificity. PCR reactions without visible bands on gel
electrophoresis or without confirmed sequence homology to the
expected target were considered negative. No-template PCR
controls (consisting of master mix, primers, and water) and sham
digest controls (template consisting of water subjected to DNA
extraction) were run with each PCR assay to monitor for
contamination.
Each subject’s extracted DNA was subjected to a human b-
globin or 18S rRNA gene PCR to assure that amplifiable DNA
was successfully extracted from the sample and to monitor for
PCR inhibitors.[30]
Participants were tested at enrollment for C. trachomatis and N.
gonorrhoeae using the APTIMA- COMBO 2 assay (Gen-Probe, San
Diego, CA) on urine, and at follow-up visits if they reported
interim risk behavior (new sex partner, .1 partner) or genitouri-
nary symptoms.
Ethics
Written informed consent was obtained from all participants.
Conduct of the study adhered to standard guidelines for research
involving human subjects, and was approved annually by the
University of Washington Human Subjects Review Committee.
Statistical methods
For the analysis, incident BV was defined by the first visit at
which a woman was found to have BV (whether at a quarterly
Incident Bacterial Vaginosis
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by Amsel criteria. After detection of an incident BV episode in a
participant, that participant was censored from the analysis. For
subanalysis, abnormal vaginal microbiota was defined by Nugent
score .3. We used Cox regression analysis to generate hazard
ratios for risk of BV acquisition. Adjustment was performed for
other statistically significant covariates. All statistical tests were
two-sided and a level of p,0.05 was considered statistically
significant. Analyses were performed using R 2.4.1 and Stata 9.2
(College Station TX, USA).
Results
The characteristics of 335 women enrolled in the overall study
are summarized in Table 1. Median age was 27 years, 24% self-
categorized as non-White, 1/3 reported a prior diagnosis of BV,
and 24% reported recent (past 90 days) sex with a male partner. At
enrollment, two women (0.6%) had C. trachomatis, and 9 (2.7%) had
symptomatic vulvovaginal candidiasis. None had N. gonorrhoeae,
trichomoniasis, or clinically evident genital herpes. Ninety-six
women (28.7%) had BV at enrollment and were excluded from the
longitudinal analysis of risks for BV acquisition, which thus
included 239 participants, as outlined in Figure 1. Of these 239
women who did not have BV at the enrollment visit, 199 returned
for at least one follow-up visit. Median duration of follow-up for
these 199 women was 381 days (interquartile range, 361–412
days), with a median number of four follow-up visits. Forty
episodes of BV occurred among these 199 women over a total of
172.6 woman-years at risk (overall incidence, 0.23 per woman-
year), with a median number of days to BV diagnosis after a visit at
which BV was not detected of 92 days (interquartile range, 89–104
days). Figure 2 depicts the incidence of BV among participants
over the course of follow-up.
The relationship between participants’ characteristic and inci-
dent BV in univariate analysis is shown in Table S1. Detection of
any of several BVAB at the enrollment visit, when participants were
free of BV, was associated with the highest risks of subsequent BV;
these included BVAB1, BVAB2, BVAB3, G. vaginalis, A. vaginae,
Leptotrichia spp, and Megasphaera-1. Detection of Lactobacillus crispatus
by PCR assay or of H2O2-producing lactobacilli by cultivation at
enrollment was associated with reduced risk. Other significant risks
for incident BV included examination in the two weeks following
menses, reportofa new femalesexpartner with a historyofBV,and
report of recent change in vaginal discharge. Despite the latter
finding, most incident BV occurred in asymptomatic women (28 of
40 cases (70%)).
Detailed analysis of sexual behavioral data revealed a direct dose-
response relationship with increasing numbers of reported episodes
of receptive oral-vulvovaginal sex. The corresponding estimated
relative risk (RR) of 1.02 per act translates to a 21% increase in risk
of BV for each additional 10 such acts in the last three months. A
similar association with receptive oral-anal sex did not reach
statistical significance (relatively few women reported this behavior).
Additional behaviors assessed for which no association with BV
acquisition was seen included other sexual activities noted, and time
to last episode of each of the behaviors (in addition to sharing sex
toys, shown) in Table 1. Of note, the median time to reported last
episodeofthespecificsexualbehaviorslistedinTable1rangedfrom
4 days (any sex) to 21 days (receptive anal sex).
Detection by PCR assay at enrollment of any of the BV-
associated bacteria listed in Table 1 was highly correlated with the
likelihood of other positive BV-associated bacteria PCR assays.
Spearman correlation coefficients between specific BVAB ranged
from 0.5to 0.77, with many greater than 3.0. Thus, the multivariate
model of risks for acquisition of BV included a composite variable
that was based on detection of any positive PCR assay for the
bacteria that were significantly associated with subsequent BV (as
listed in Table S1). Table 2 summarizes the results of the
multivariate analysis (Table 2). In an analysis that adjusted for
report of new sex partner with a history of BV, detection of any of
BVAB1, BVAB2, BVAB3, P. lacrimalis, Leptotrichia species, Atopobium
species, G. vaginalis Megasphaera-1, and L. crispatus remained
significantly associated with BV acquisition.
Discussion
Among women without BV who were subsequently followed for
an average of one year, we found that detection of several BV-
Table 1. Characteristics of 335 subjects according to
presence of bacterial vaginosis at enrollment.
BV* present BV absent
N=96 N=239
Age – years
Median 25 25
Range 15–35 17–34
Race (self-defined) – no. (%)
{
White 69 (72) 185 (77)
Black 7 (7) 9 (4)
Nonwhite, other than black 17 (18) 39 (16)
Declined to provide race data 3 (3) 6 (3)
Sex with women, prior 3 months – no. (%) 80 (84) 197 (82)
Female sex partners, prior 90 days
Median no. 1 1
Range 0–7 0–5
Sex with men, prior 3 months – no. (%) 19 (20) 61 (26)
Male sex partners, prior 90 days
{
Median no. 0 0
Range 0–5 0–4
Consistent condom use – no (%) 6 (38) 10 (19)
Current cigarette smoking 33 (40) 66 (32)
Douching, past month 5 (5) 9 (4)
Hormonal contraception use, past 60 days 9 (10) 26 (11)
Vaginal symptoms
1 present – no (%) 34 (35) 51 (21)
Concurrent genitourinary infection present
–n o( % )
Vulvovaginal candidiasis 2 (2) 18 (8)
Trichomoniasis 0 (0) 0 (0)
Chlamydia trachomatis 2( 2 ) 1( ,1)
*BV = bacterial vaginosis at the enrollment visit; defined by presence of Amsel
criteria and confirmed by Nugent score .6. The 239 women without BV
comprised the sub-population eligible for the prospective analysis of
subsequent BV acquisition.
{Subjects were permitted to choose more than one category to describe their
race. ‘‘White’’ refers to those who chose only ‘White’ to describe their race;
‘‘Black’’ refers to those who chose ‘‘Black or African American’’ even if they also
chose another race, and ‘‘Nonwhite’’ refers to those who chose any other race
besides white.
{Among women who reported vaginal intercourse with a male partner in the
prior three months.
1Defined as change in amount, color, or odor of vaginal discharge.
doi:10.1371/journal.pone.0011139.t001
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negative) visit predicted subsequent acquisition of BV. Conversely,
detection of L. crispatus at enrollment was associated with reduced
risk of subsequent BV acquisition. Women were also more likely to
have BV diagnosed when they presented in the two weeks after
menses. The significant association between detection of BVAB at
enrollment and BV acquisition remained significant after adjusting
for timing of examination relative to participants’ menstrual cycles
and new sex partner with a history of BV. Notably, although over
80% of participants without BV at enrollment had Lactobacillus
crispatus at enrollment as detected by PCR assay, 20% acquired BV
in the year of follow-up. The incidence of BV that we observed in
our participants—0.23 episodes/woman-year—was only slightly
lower than that reported in a larger yearlong prospective study of
young heterosexual women.[17]
Despite collection of extensive sexual risk behaviors using CASI
during follow-up, only report of a new female sex partner who
provided a history of BV was clearly associated with increased risk
of BV acquisition in univariate analysis. The dose-response
relationship we observed between risk of BV acquisition and
increasing reported number of episodes of receptive vulvovaginal
sex is of interest (as is the less significant but directionally similar
association with receptive oral-anal sex), although we did not
observe these associations when these behaviors were analyzed
using other measures (for example, report of any behavior vs. not,
or time to last behavior). Thus, these findings support further
detailed investigation of the potential role of these behaviors in
future BV acquisition studies, to confirm the associations we
detected. Given the absence of associations between other recent
sexual practices and BV acquisition, the significance of association
between BV and report of a new female partner with BV history
remains unclear. As we have previously reported, an intervention
to prevent sexual transmission of vaginal fluid in this cohort –
despite succeeding in reducing the risk of sexual practices targeted
by the intervention—failed to reduce the risk of BV acquisi-
tion.[31] Our inability to establish a role for sexual transmission of
BV in this cohort may relate to several factors, including imprecise
assessment of the time of sexual exposure to acquisition of a
‘‘precipitant’’ for BV, the possibility that multiple sexual practices
may be involved and are often practiced concurrently, or, as is
highly likely, that BV pathogenesis is multifactorial: while
unprotected sex is likely contributory, other factors are probably
involved.
We have previously reported that among women with BV in
this cohort who were treated with vaginal metronidazole,
predictors of treatment failure included detection of specific
BVAB at baseline, including the Clostridia-like bacteria BVAB1,
BVAB2 and BVAB3, Peptoniphilus lacrimalis and Megasphaera
phylotype 2, as well as failure to adhere to five days of vaginal
metronidazole.[32] Importantly, report of no specific sexual
practices with either male or female partners in the month after
treatment predicted either persistent bacterial vaginosis or
abnormal microbiota. The latter finding is notable, as others have
reported that unprotected vaginal intercourse is associated with
recurrent BV. However, as we note below, our ability to detect
such associations was limited by the relatively small number of
outcomes we observed and the selected population we studied.
Our observation that detection of specific BVAB in vaginal fluid
weeks to months prior to a diagnosis of BV suggests that changes
in vaginal microbiota may precede the development of BV by a
considerable time period. Bacterial vaginosis is a heterogeneous
syndrome characterized by diverse microbiota, some of which
might be essential ‘‘founder’’ species necessary to establish an
environment favorable to progression to BV. For example, a
tenacious biofilm on vaginal epithelium may lead to antibiotic
failure or create a persistent reservoir of bacteria further increasing
women’s risk of treatment failure.[33] Concentrations of bacteria
at the earliest stages of biofilm formation may be insufficient to
cause BV, yet may provide a critical layer of bacterial cells that
Figure 1. Study flow diagram.
doi:10.1371/journal.pone.0011139.g001
Figure 2. Incidence of bacterial vaginosis (BV) among women
with no BV at study entry.
doi:10.1371/journal.pone.0011139.g002
Table 2. Multivariate analysis of risks for acquisition of
bacterial vaginosis (BV).
Characteristic Hazard ratio P-value
(95% CI)
Enrollment PCR+ for BVAB1, BVAB2, BVAB3, P.
lacrimalis, Leptotrichia, Atopobium, Megasphaera
spp or G. vaginalis
3.02 (1.12–8.13) 0.03
Enrollment PCR+ for L. crispatus 0.16 (0.07–0.36) ,0.001
#14 days since start of menstrual cycle 3.49 (1.36–8.93) 0.01
New sex partner with history of BV 2.96 (0.38–23.2) 0.30
doi:10.1371/journal.pone.0011139.t002
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nity. These early colonizers may be detected by species-specific
PCR assays as described above. In some women assessed
frequently (for example, daily), rapid shifts in vaginal microbiota
as measured by quantitative PCR assays and by Nugent score are
evident.[34] Studies focused on the kinetics of acquisition of
vaginal bacterial communities are likely to be very useful for
understanding the pathogenesis of BV.
In our participants, BV was not associated with risk factors that
others have identified, including failure to use con-
doms[14,16,35,36] and other sexual behaviors with male part-
ners.[17] This may partly be explained by a low incidence of
sexual contact with men among our subjects in the month after
treatment. However, given the high prevalence of BV among
lesbians, the frequency of concordant BV in female sex partners,
and the observation that report of sex with another woman was
associated with increased risk of recurrence in one prospective
study,[14] we were surprised not to find a clearer association
between BV acquisition and sexual behaviors with female partners
in the month after treatment. This could be explained by small
numbers of women in some subgroups, or by an overriding role of
baseline vaginal microbiota associated with BV promoting
persistence in this group —rather than ‘‘reinfection’’ or exposure
to another causative factor through sex[14,16,35,36].
Limitations
The main limitation of our analysis is that PCR assays for
individual BVAB in vaginal fluid were obtained only at the
enrollment visit; it is likely that more proximate detection of these
bacteria in women without BV to the actual BV episode will
demonstrate an even higher risk for subsequent BV acquisition.
Prospective studies that apply PCR assays to frequent serial
measurements—ideally through self-collection of vaginal swabs—
would be the ideal approach to clarifying the temporal sequence of
events that lead to BV. Nonetheless, several of the BVAB we
detected at the enrollment visit were associated with markedly
elevated risk of subsequent BV. Second, the interpretation of our
multivariate analysis is limited by two factors: the relatively small
numbers of women who had some individual BVAB detected by
PCR assay, and the high degree of correlation among BVAB in
that each species is frequently found as part of a larger community
of BVAB. For this reason, we did not analyze individual BVAB in
our multivariate analysis. Third, our subjects were selected on the
basis of reporting sex with other women. Although 24% also
reported sex with men in the three months prior to enrollment,
they are unlikely to be representative of exclusively heterosexual
women, a group that should be studied in similar fashion and to
whom our findings may not necessarily apply. However, the fact
that our subjects infrequently reported vaginal intercourse with
male partners in the month after treatment might actually be
advantageous in helping to define the role of vaginal microbiology
in determining whether antecedent vaginal colonization of these
bacteria have an independent role in predicting future incidence of
BV. Finally, we relied on self-report of sexual behaviors to estimate
subsequent BV risk, although we used CASI to minimize under- or
over-reporting of these behaviors.
Our findings raise several important areas for future research.
First, comparative assessments of risks for acquisition of BV,
including molecular characterization of baseline microbiology of
BVAB, need to be performed in heterosexual women; these efforts
should help to define whether the molecular epidemiology of
bacterial vaginosis differs from that of women who have sex with
women, and to further help define a potential role of unprotected
vaginal intercourse with male partners in BV incidence. Second,
our BVAB-specific assays were qualitative. Quantitative polymer-
ase chain reaction assays applied to vaginal fluid samples obtained
in our subjects may offer more precise predictive value for incident
BV, though they are typically less specific than performing
sequence analysis on the amplicons as was performed in this study.
Third, more frequent sampling (for example, daily or weekly) for
application of bacterium-specific PCR assays in women without
BV should help to better define the evolution of vaginal microbiota
towards the ‘‘tipping point’’ of actual BV; these measures should
be thoughtfully integrated with concomitant collection of behav-
ioral data to further explore potential links with sexual practices.
Finally, the establishment of consensus definitions for incidence,
persistence and recurrence of BV would assist in progress towards
describing the natural history of this condition. Whether risk
factors that promote incidence are the same as those that promote
persistence or recurrence is not clear.
In summary, our findings suggest that vaginal colonization with
key BVABs among women with no BV is an independent risk
factor for incident BV. Because BV may confer an increased risk of
poor pregnancy outcome and HIV acquisition and predict upper
genital tract disease, defining microbiological risk factors for new
episodes of BV may offer new approaches to prevention.
Supporting Information
Table S1 Associations between participants’ characteristics &
acquisition of bacterial vaginosis (BV) in univariate analysis.
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